<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-36 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-36</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-36</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-2.html">extraction-schema-2</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <p><strong>Paper ID:</strong> paper-fcc794d59b6567b127253557b5b02bda2e201484</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/fcc794d59b6567b127253557b5b02bda2e201484" target="_blank">Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing</a></p>
                <p><strong>Paper Venue:</strong> Cell</p>
                <p><strong>Paper TL;DR:</strong> Exome and genome sequences and whole-genome sequence analysis revealed frequent structural rearrangements, including in-frame exonic alterations within EGFR and SIK2 kinases, which are attractive targets for biological characterization and therapeutic targeting of lung adenocarcinoma.</p>
                <p><strong>Cost:</strong> 0.019</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e36.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e36.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>U2AF1</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>U2 small nuclear RNA auxiliary factor 1</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A core spliceosome factor with a recurrent hotspot (p.S34F) discovered mutated in a subset of lung adenocarcinomas; proposed as a candidate driver via altered RNA splicing.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Whole-exome and whole-genome sequencing with statistical significance analysis (InVEx) and clinical correlation</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>183 primary lung adenocarcinomas (27 never-smokers, 17 light smokers, 118 heavy smokers); overall the study reports that 47% of tumors harbored a known proliferative driver, implying ~53% lacked a canonical RTK/RAS/RAF proliferative-driver.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td>Defined as lacking mutations or high-level focal amplification in canonical proliferative signaling genes (examples used in the paper: EGFR, KRAS, BRAF, ERBB2, ALK/RET/ROS1 fusions, and other Sanger Cancer Gene Census proliferative genes).</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>Recurrent U2AF1 p.S34F and other nonsynonymous U2AF1 mutations (spliceosome alteration)</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>Genetic mutation (spliceosome / RNA-processing factor)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>U2AF1 was a statistically significant hit in PPH2 InVEx (p = 2.0 × 10^-6), mutated in ~3% of cases (5/183) with four cases sharing the identical c.101C>T (p.S34F) hotspot; one U2AF1-mutant case co-occurred with KRAS but others did not. U2AF1 mutation status associated with reduced progression-free survival (U2AF1 p = 0.00011, log-rank). The paper notes analogous recurrent U2AF1 hotspot mutations previously reported in myelodysplastic syndromes, and this is the first report (in this paper) in an epithelial tumor.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>Low prevalence (≈3%) so cannot explain the majority of driver-negative tumors; observed co-occurrence with canonical oncogenes in at least one case (suggesting it may be cooperating rather than sole driver); no mechanistic/functional assays in this paper showing direct oncogenic mechanism in lung adenocarcinoma (functional inference based on hotspot recurrence and analogy to hematologic malignancy).</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>Altered RNA splicing from recurrent U2AF1 hotspot mutations provides an alternative route to tumorigenesis or progression in tumors lacking canonical RTK/RAS/RAF alterations, possibly by dysregulating splicing of transcripts important for growth or survival.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e36.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e36.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>RBM10</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>RNA-binding motif protein 10</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>An RNA-binding protein frequently subject to truncating (nonsense/frameshift/splice-site) mutations in lung adenocarcinoma, nominated as a candidate tumor suppressor/driver via disruption of RNA regulation.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Whole-exome sequencing and InVEx loss-of-function statistical analysis</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>183 lung adenocarcinomas (see above); RBM10 truncating mutations observed in 12/183 cases (~7%).</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td>Same as above: absence of canonical proliferative signaling alterations (EGFR/KRAS/BRAF/ALK/RET/ROS1/etc.).</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>Truncating (loss-of-function) mutations in RBM10</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>Genetic mutation (truncating mutations disrupting an RNA-binding protein)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>RBM10 was mutated in 12/183 cases (≈7%) with recurrent nonsense/frameshift/splice-site events; global PPH2 InVEx analysis showed enrichment (p = 0.00042 reported for RBM10 in context of truncating events). RBM10 is highly expressed in lung adenocarcinoma cell lines and its mutations co-occurred with known oncogenes (KRAS, EGFR, PIK3CA), indicating recurrent selection.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>Frequent co-occurrence with canonical drivers in some cases argues RBM10 mutations may be cooperating or passenger in some tumors rather than sole drivers of proliferation in driver-negative tumors; no direct functional validation in this study demonstrating RBM10 loss is sufficient for transformation in lung epithelium.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>Loss of RBM10-mediated RNA regulation (via truncating mutations) contributes to tumorigenesis through widespread alterations of mRNA processing/splicing, providing an alternative mechanism in tumors lacking canonical RTK/RAS/RAF drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e36.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e36.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Spliceosome alterations (aggregate)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Mutations in spliceosome component genes (e.g., U2AF1, SF3B1, U2AF2, PRPF40B)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Recurrent mutations across multiple spliceosome genes were observed, suggesting RNA splicing deregulation as a recurring mechanism in a subset of tumors.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Whole-exome sequencing with mutation aggregation and significance testing</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>183 tumors; aggregate spliceosome gene mutations identified in multiple cases (U2AF1 in ~3% plus additional nonsynonymous events in SF3B1, U2AF2, PRPF40B in 14 additional cases).</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td>As above; focus on tumors without canonical RTK/RAS/RAF pathway alterations.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>Dysregulated RNA splicing due to mutations in spliceosome components</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>Genetic (somatic missense/truncating mutations in splicing machinery)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>Beyond U2AF1 hotspot, the study found nonsynonymous mutations in several spliceosome genes across the cohort (SF3B1, U2AF2, PRPF40B), indicating recurrence of RNA-processing gene alteration; U2AF1 showed statistical enrichment and survival correlation.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>Most spliceosome events are individually infrequent; functional consequences on specific transcripts in lung adenocarcinoma are not demonstrated in this paper; co-occurrence with other drivers in some cases complicates interpretation whether spliceosome mutations are primary drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>A subset of lung adenocarcinomas lacking canonical proliferative drivers may rely on perturbation of pre-mRNA splicing to reprogram gene expression networks that promote growth or survival.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e36.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e36.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ARID1A</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>AT-rich interaction domain 1A (SWI/SNF chromatin remodeling complex subunit)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>An epigenetic regulator mutated with truncating events in lung adenocarcinoma, implicating chromatin remodeling disruption as a candidate alternative driver mechanism.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Whole-exome sequencing with LOF InVEx analysis and mapping to cancer hallmarks</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>183 tumors; ARID1A mutated in ~8% of cases with significant enrichment of truncating mutations (CGC LOF InVEx p = 0.027).</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td>Lack of canonical RTK/RAS/RAF alterations as described above.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>Inactivating (truncating) mutations of ARID1A disrupting SWI/SNF chromatin remodeling</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>Genetic mutation affecting epigenetic regulation (chromatin remodeler loss-of-function)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>ARID1A was mutated in ~8% of cases, showed significant enrichment of truncating events (p = 0.027 in CGC LOF InVEx), and is part of a broader set of epigenetic regulators (including SMARCA4, SETD2, BRD3) mutated in the cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>Mutation frequency is modest; no direct functional assays in this paper linking ARID1A loss to transformation in lung epithelial models; ARID1A mutations may explain only a minority of driver-negative tumors.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>Disruption of chromatin remodeling (SWI/SNF complex) by ARID1A loss creates epigenetic states that promote tumorigenesis and may substitute for canonical proliferative pathway activation in some tumors.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e36.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e36.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>SMARCA4 & epigenetic regulators</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>SMARCA4 (BRG1) and other chromatin / epigenetic regulators (SETD2, BRD3, etc.)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Multiple epigenetic regulators were recurrently mutated (e.g., SMARCA4, SETD2, BRD3) suggesting epigenetic deregulation is a recurrent theme and a candidate mechanism in tumors lacking canonical proliferative drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Whole-exome sequencing with aggregate analysis and hallmark mapping</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>183 tumors; SMARCA4, SETD2, BRD3 and others were mutated at varying frequencies (SMARCA4 reported among previously known mutated genes; BRD3 identified in LOF InVEx).</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td>Absence of canonical RTK/RAS/RAF pathway mutations or amplifications.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>Mutations in chromatin remodeling and epigenetic regulator genes leading to epigenetic deregulation</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>Genetic mutation causing epigenetic dysregulation</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>The study found recurrent mutations in multiple epigenetic regulators (SMARCA4 among previously reported genes; SETD2 and BRD3 nominated by InVEx). Authors propose an 'eleventh hallmark' of epigenetic and RNA deregulation, estimating 10% (SMARCA4 alone) to 22% (including nominated genes) of cases may be affected.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>Many epigenetic events are of modest frequency and lack direct functional validation in this paper; mapping of SMARCA4 to a specific classical cancer hallmark was ambiguous in the study (authors note it could not be clearly mapped), and these events do not account for all driver-negative tumors.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>Epigenetic dysregulation (via mutations in SWI/SNF subunits, histone modifiers, and bromodomain proteins) drives tumorigenesis in a subset of lung adenocarcinomas lacking canonical RTK/RAS/RAF alterations by altering transcriptional programs required for proliferation, survival, or other hallmarks.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e36.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e36.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>SIK2 / ROCK1 rearrangements</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>SIK2 (salt-inducible kinase 2) and ROCK1 (Rho-associated kinase 1) in-frame structural variants</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>In-frame structural rearrangements (duplications) affecting kinase domains of SIK2 and ROCK1 were identified in whole-genome sequences of tumors that lacked mutations in known lung adenocarcinoma oncogenes, making them candidate alternative drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Whole-genome sequencing with rearrangement detection and validation (paired-end and split-read mapping, qPCR validation for SIK2 duplication)</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>24 whole-genome sequenced tumor/normal pairs (subset of the 183); in-frame kinase rearrangements detected in some genomes, specifically SIK2 kinase-domain duplication and a 19-exon duplication in ROCK1.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td>The paper explicitly notes these kinase rearrangements occurred in tumors 'without mutations in lung adenocarcinoma oncogenes' (i.e., lacking canonical driver mutations/fusions).</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>In-frame kinase domain duplication/duplication events in SIK2 and ROCK1 as activating structural variants</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>Genetic structural rearrangement (in-frame duplication affecting kinase domains)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>WGS found an in-frame duplication in SIK2 located 15 amino acids upstream of a known activation site (Thr-175) and a large multi-exon duplication in ROCK1; SIK2 duplication was validated by qPCR. The paper highlights these events specifically in tumors lacking known oncogene mutations, suggesting they could substitute as proliferative drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>No functional assays are presented in this paper demonstrating these specific rearrangements are oncogenic in lung cells; events were identified in a small WGS subset (24 genomes) and may be rare, so they cannot account for most driver-negative tumors without further validation.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>Structural activation of noncanonical kinases (via in-frame duplications) can provide proliferative signaling in tumors that lack RTK/RAS/RAF pathway alterations, representing alternative genetic routes to sustained proliferation.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e36.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e36.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>STK11 / KEAP1 (metabolic / stress pathways)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>STK11 (LKB1) and KEAP1 (Kelch-like ECH-associated protein 1)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Tumor suppressors involved in metabolic regulation (STK11/LKB1) and oxidative stress response (KEAP1) are recurrently mutated and may represent non-RTK/RAS/RAF mechanisms contributing to tumorigenesis and tumor metabolism.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Whole-exome sequencing with frequency reporting and correlation analyses</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>183 tumors; STK11 mutations observed in ~15% of cases, KEAP1 in ~12% (frequencies reported in summary of significantly mutated genes).</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td>Absence of canonical RTK/RAS/RAF pathway alterations as described above.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>Loss-of-function mutations in STK11 and KEAP1 altering cellular metabolism, energy sensing, and oxidative stress pathways</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>Genetic mutation affecting metabolic/stress-response pathways (tumor suppressor loss)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>STK11 and KEAP1 were among significantly mutated genes (STK11 ~15%, KEAP1 ~12%); STK11 driver alterations were significantly enriched in mutation spectrum cluster 2 (p = 0.0026). The authors note these genes are frequently mutated in lung adenocarcinoma and can impact metabolic and redox homeostasis, suggesting a mechanistic route distinct from canonical proliferative signaling.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>These genes are not universally mutated in driver-negative tumors; STK11/KEAP1 alterations may often co-occur with other driver events and their presence does not fully explain the many tumors lacking canonical proliferative drivers; the paper does not provide functional experiments within this study to directly demonstrate that these mutations substitute for RTK/RAS/RAF pathway activation.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>Metabolic reprogramming and altered oxidative stress handling due to STK11 or KEAP1 loss can promote tumor growth and survival independently of RTK/RAS/RAF activation, constituting an alternative molecular route in driver-negative tumors.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e36.7">
                <h3 class="extraction-instance">Extracted Data Instance 7 (e36.7)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Epigenetic & RNA deregulation hallmark</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Proposed eleventh cancer hallmark: epigenetic and RNA deregulation</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The authors propose adding 'epigenetic and RNA deregulation' as an additional hallmark of cancer to capture recurrent alterations in chromatin remodelers and RNA-processing genes observed in lung adenocarcinoma.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Integrative analysis: mapping significantly mutated genes to Hanahan & Weinberg hallmarks</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>183 tumors; authors estimate this proposed hallmark affects 10% (SMARCA4 only) to 22% (including nominated genes) of cases based on mutated epigenetic and splicing regulators.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td>Tumors lacking canonical proliferative-driver alterations but showing mutations in epigenetic or RNA-processing genes.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>Aggregate perturbation of chromatin remodeling and RNA processing (mutations in SMARCA4, ARID1A, U2AF1, RBM10, SETD2, BRD3, etc.) as an alternative class of driver alterations</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>Genetic alterations with epigenetic and transcriptomic consequences (epigenetic regulator mutations and spliceosome gene mutations)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>Multiple recurrently mutated genes in the cohort are epigenetic regulators or RNA/splicing factors (U2AF1, RBM10, ARID1A, SMARCA4, SETD2, BRD3). The authors quantified that including these genes implicates 10–22% of cases and propose this as a distinct hallmark to account for tumors without canonical proliferative-driver alterations.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>Even combined, these events explain a minority of tumors; many epigenetic/splicing alterations lack direct functional validation in lung models in this study; the majority of driver-negative tumors remain unexplained, and other mechanisms (noncoding mutations, methylation, microenvironment) are not fully assayed here.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>Perturbation of chromatin state and RNA processing is a recurrent, mechanistically distinct route to tumorigenesis in lung adenocarcinoma and can account for some tumors that lack mutations in RTK/RAS/RAF proliferative pathways.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e36.8">
                <h3 class="extraction-instance">Extracted Data Instance 8 (e36.8)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered molecular drivers, mechanisms, or pathways in lung adenocarcinomas lacking known RTK/RAS/RAF pathway alterations, including genetic, epigenetic, metabolic, or microenvironmental factors, as well as any supporting or refuting evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Immune / microenvironmental gap</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Absence of recurrent mutations linked to immune evasion or tumor-promoting inflammation</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The study found no recurrently mutated genes that could be directly mapped to the hallmarks 'avoiding immune destruction' or 'tumor-promoting inflammation', leaving microenvironmental drivers largely unexplained by coding somatic alterations.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Whole-exome/whole-genome sequencing with hallmark mapping and manual annotation</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>183 tumors; authors mapped 25 genes to hallmarks and found none mapping to immune/ inflammation hallmarks.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_definition</strong></td>
                            <td>Tumors lacking canonical RTK/RAS/RAF alterations and lacking mapped genetic drivers for immune/microenvironmental hallmarks.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_driver</strong></td>
                            <td>Not directly identified; the paper highlights the microenvironment/immune-related hallmark as an area with no recurrently mutated genes identified and suggests non-genetic or noncoding mechanisms or tumor–host interactions could drive these phenotypes.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_type</strong></td>
                            <td>Microenvironmental / non-genetic mechanisms (hypothesized; not identified by this study)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_summary</strong></td>
                            <td>Manual mapping of the 25 significantly mutated genes to cancer hallmarks returned no genes linked to avoiding immune destruction or tumor-promoting inflammation; authors explicitly note this phenotypic gap and suggest these hallmarks may be driven by mechanisms not assayed (e.g., noncoding alterations, methylation, stromal interactions).</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>Lack of evidence is not evidence of absence: the study did not include comprehensive immune profiling, RNA-seq for immune signatures, or methylation/noncoding analyses that could reveal microenvironmental mechanisms; thus the paper cannot confirm or refute specific microenvironmental drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>model_or_hypothesis</strong></td>
                            <td>Phenotypes related to immune evasion and tumor-associated inflammation in many lung adenocarcinomas may be driven by non-coding genetic events, epigenetic changes, transcriptional reprogramming, or interactions with the tumor microenvironment rather than recurrent coding mutations detectable by the assays used here.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Somatic mutations affect key pathways in lung adenocarcinoma <em>(Rating: 2)</em></li>
                <li>Diverse somatic mutation patterns and pathway alterations in human cancers <em>(Rating: 1)</em></li>
                <li>Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer <em>(Rating: 1)</em></li>
                <li>A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing <em>(Rating: 1)</em></li>
                <li>Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>